Fusion Antibodies plc

Default features description for sign up page.

Updates

Regulatory News

Company Presentations

Webinars

Board Profiles

Company Profile

Home

Fusion Deep Dive

Advisers

Company Information & FAQs

Corporate Governance

Share Price

New investors

Shareholder Information

Raleway

In this episode, Chief Scientific Officer Richard Buick takes a deep dive into OptiMAL®, Fusion Antibodies’ cutting-edge antibody discovery platform.

Richard explains what makes OptiMAL® unique—combining an optimised antibody library with a mammalian display platform to create a powerful tool for therapeutic antibody development. Designed from an actual human repertoire, OptiMAL® selects for manufacturability and target binding, ensuring high-quality candidates for drug discovery. With a proprietary, patent-pending design, this novel library delivers antibodies that can’t be generated anywhere else.

Watch now to explore the science behind OptiMAL® and its impact on next-generation antibody discovery.

Deep Dive Series: OptiMAL®